Borosil Scientific Ltd posted a standalone revenue of Rs 427.53 crore for FY 2025-26, reflecting an 8.93% year-on-year growth. The company reported a consolidated revenue of Rs 467.34 crore with a PAT of Rs 34.58 crore. Management is focusing on high-value instrumentation and automated packaging to boost margins, while maintaining a lean cash position for upcoming capital expenditure. No dividend has been recommended for the fiscal year as the firm prioritizes capacity expansion and technology upgrades.
Borosil Scientific FY26 Financial and Operational Performance
Standalone Revenue stood at Rs 427.53 crore with a PAT of Rs 39.72 crore.
Consolidated Revenue reached Rs 467.34 crore with a PAT of Rs 34.58 crore.
Reader Takeaway: Revenue growth remains steady, but cash conservation for expansion projects and input cost volatility require close monitoring.
What just happened
Borosil Scientific has released its annual performance report for FY 2025-26. The company achieved an 8.93% YoY growth in standalone revenue and a 6.58% growth on a consolidated basis. The firm’s EBITDA margins were reported at 18.76% (standalone) and 15.35% (consolidated). Notably, the board has not recommended a dividend for the year, opting to preserve cash for strategic growth initiatives and capital expenditure.
Why this matters
The company is pivoting its product mix toward high-value, technology-enabled segments such as digital burettes and siliconized vials. By investing in robotics at its Nashik facility and achieving TPM certification at Bharuch, the firm is positioning itself to capture demand from the domestic pharmaceutical and specialty chemical sectors. This transition toward higher-margin instrumentation is central to its long-term growth strategy.
Risks to watch
Management cited sensitivity to global energy price fluctuations and the rising cost of specialized raw materials, such as glass tubing. Furthermore, the company continues to navigate pricing pressures from both unorganized domestic players and international competitors. Export markets also presented headwinds, making domestic performance the primary engine for the current fiscal period.
What to track next
Investors should monitor the scaling of the LabQuest instrumentation portfolio and the contribution of new high-value products to consolidated margins. The execution timeline of ongoing capacity expansion projects remains a critical factor for future valuation.